237 related articles for article (PubMed ID: 2826030)
1. Feline leukemia virus: current status of the feline induced immune depression and immunoprevention.
Olsen RG; Lewis MG; Lafrado LJ; Mathes LE; Haffer K; Sharpee R
Cancer Metastasis Rev; 1987; 6(3):243-60. PubMed ID: 2826030
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunologic aspects of FeLV-induced immunosuppression.
Ogilvie GK; Tompkins MB; Tompkins WA
Vet Microbiol; 1988 Jul; 17(3):287-96. PubMed ID: 2847393
[TBL] [Abstract][Full Text] [Related]
3. FeLV-FAIDS-induced immunodeficiency syndrome in cats.
Mullins JI; Hoover EA; Overbaugh J; Quackenbush SL; Donahue PR; Poss ML
Vet Immunol Immunopathol; 1989 May; 21(1):25-37. PubMed ID: 2549691
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor alpha levels in cats experimentally infected with feline immunodeficiency virus: effects of immunization and feline leukemia virus infection.
Lehmann R; Joller H; Haagmans BL; Lutz H
Vet Immunol Immunopathol; 1992 Dec; 35(1-2):61-9. PubMed ID: 1337403
[TBL] [Abstract][Full Text] [Related]
5. Feline immunodeficiency syndrome--a comparison between feline T-lymphotropic lentivirus and feline leukemia virus.
Yamamoto JK; Pedersen NC; Ho EW; Okuda T; Theilen GH
Leukemia; 1988 Dec; 2(12 Suppl):204S-215S. PubMed ID: 2848998
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive properties of a virion polypeptide, a 15,000-dalton protein, from feline leukemia virus.
Mathes LE; Olsen RG; Hebebrand LC; Hoover EA; Schaller JP; Adams PW; Nichols WS
Cancer Res; 1979 Mar; 39(3):950-5. PubMed ID: 218725
[TBL] [Abstract][Full Text] [Related]
7. Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response.
Mathes LE; Polas PJ; Hayes KA; Swenson CL; Johnson S; Kociba GJ
Antimicrob Agents Chemother; 1992 Dec; 36(12):2715-21. PubMed ID: 1336345
[TBL] [Abstract][Full Text] [Related]
8. Determinants of susceptibility and resistance to feline leukemia virus infection. II. Susceptibility of feline lymphocytes to productive feline leukemia virus infection.
Rojko JL; Hoover EA; Finn BL; Olsen RG
J Natl Cancer Inst; 1981 Oct; 67(4):899-910. PubMed ID: 6268886
[TBL] [Abstract][Full Text] [Related]
9. Immunodeficiency in latent feline leukemia virus infections.
Lafrado LJ; Dezzutti CS; Lewis MG; Olsen RG
Vet Immunol Immunopathol; 1989 May; 21(1):39-46. PubMed ID: 2549692
[TBL] [Abstract][Full Text] [Related]
10. Reversal of feline retroviral suppression by indomethacin.
Lewis MG; Fertel RH; Olsen RG
Leuk Res; 1985; 9(12):1451-6. PubMed ID: 3001436
[TBL] [Abstract][Full Text] [Related]
11. Control of feline leukaemia virus.
Weijer K; Uytdehaag FG; Osterhaus AD
Vet Immunol Immunopathol; 1989 May; 21(1):69-83. PubMed ID: 2549695
[TBL] [Abstract][Full Text] [Related]
12. A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine.
Schlecht-Louf G; Mangeney M; El-Garch H; Lacombe V; Poulet H; Heidmann T
J Virol; 2014 Jan; 88(2):992-1001. PubMed ID: 24198407
[TBL] [Abstract][Full Text] [Related]
13. Feline oncornavirus-associated cell membrane antigen: a viral and not a cellularly coded transformation-specific antigen of cat lymphomas.
Vedbrat SS; Rasheed S; Lutz H; Gonda MA; Ruscetti S; Gardner MB; Prensky W
Virology; 1983 Jan; 124(2):445-61. PubMed ID: 6186079
[TBL] [Abstract][Full Text] [Related]
14. Feline leukemia virus-induced immunodeficiency syndrome in cats as a model for evaluation of antiretroviral therapy.
Hoover EA; Zeidner NS; Perigo NA; Quackenbush SL; Strobel JD; Hill DL; Mullins JI
Intervirology; 1989; 30 Suppl 1():12-25. PubMed ID: 2540109
[TBL] [Abstract][Full Text] [Related]
15. [Vaccination of cats against infection with feline leukemia virus (FeLV): first recombinant vaccine and the effect of a pre-existing infection with feline immunodeficiency virus (FIV)].
Hofmann-Lehmann R; Aubert A; Wolfensberger C; Cronier J; Lutz H
Schweiz Arch Tierheilkd; 1994; 136(10):340-51. PubMed ID: 7801087
[TBL] [Abstract][Full Text] [Related]
16. FeLV-induced immunosuppression through alterations in signal transduction: down regulation of protein kinase C.
Dezzutti CS; Wright KA; Lewis MG; Lafrado LJ; Olsen RG
Vet Immunol Immunopathol; 1989 May; 21(1):55-67. PubMed ID: 2549694
[TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression.
Patel M; Carritt K; Lane J; Jayappa H; Stahl M; Bourgeois M
Clin Vaccine Immunol; 2015 Jul; 22(7):798-805. PubMed ID: 25972402
[TBL] [Abstract][Full Text] [Related]
18. Feline leukemia virus infection and diseases.
Hoover EA; Mullins JI
J Am Vet Med Assoc; 1991 Nov; 199(10):1287-97. PubMed ID: 1666070
[TBL] [Abstract][Full Text] [Related]
19. Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E.
Langhammer S; Hübner J; Kurth R; Denner J
Immunology; 2006 Feb; 117(2):229-37. PubMed ID: 16423059
[TBL] [Abstract][Full Text] [Related]
20. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom.
Osterhaus A; Weijer K; Uytdehaag F; Jarrett O; Sundquist B; Morein B
J Immunol; 1985 Jul; 135(1):591-6. PubMed ID: 2987351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
